Abstract:
PURPOSE: Provided are a chiral salen derivative used as a chiral ligand in an asymmetric epoxidation of olefin for producing chiral epoxy compounds and a chiral salen-metal derivative used as a chiral catalyst in the asymmetric epoxidation of olefin. CONSTITUTION: The chiral salen derivative is represented by the formula 1 and the chiral salen-metal derivative is represented by the formula 3, wherein R is C1-C24 straight or branched alkyl, halogen, alcohol, mercapto, or carboxyl-substituted C1-C24 straight or branched alkyl, cycloalkyl, aryl, or heteroaryl, H(1) and H(2) are trans each other, M is a transition metal ion such as Cr, Mn, V, Fe, Mo, W, Ru, Co, Ti, or Os, and A is an anion such as Cl-, CH3COO-, PF6-, or SbF6-.
Abstract:
본 발명은 (+)-렌티지노신의 신규 제조방법 및 이의 제조방법 중에 합성되는 신규 중간체 화합물에 관한 것이다. 본 발명의 제조방법에 의하면 고 광학순도를 가지는 (+)-렌티지노신을 고 수율로 제조할 수 있으며, 특히 제조공정이 손쉬워 대량생산 방법으로 유용하다.
Abstract:
The present invention relates to a 4-membered cyclic nitrogen compound which can be used as a therapeutic agent or a preventive agent for depression, mental disease, premature ejaculation, or neuropathic pain by preventing re-uptake of certain neurotransmitters with high efficiency; a pharmaceutical composition which can inhibit serotonin and dopamine or norepinephrine re-uptake and has a high therapeutic or prophylactic effect against depression, mental disease, premature ejaculation, or neuropathic pain; and a pharmaceutical formulation comprising the same.
Abstract:
The present invention relates to a novel preparation method of (+)-polyoxamic acid and a novel intermediate compound synthesized while the preparation method is performed. According to the present invention, (+)-polyoxamic acid having a high optical purity can be produced in high yield. Especially, the preparation process is simple and thus can be advantageously used for the mass production.
Abstract:
PURPOSE: A urea derivative is provided to selectively suppress the action of mPTP in the brain, thereby being used as a neuroprotective agent which improves the action of the mitochondria. CONSTITUTION: A urea derivative is denoted by chemical formula 1. A method for preparing the urea derivative comprises the steps of making a compound of chemical formula 2 react with isocyanate compounds or isothiocyanate compounds. The compound of chemical formula 2 is prepared by making a compound of chemical formula 3 react with benzyl halide compounds. A pharmaceutical composition for suppressing the action of mPTP contains the urea derivative or a pharmaceutically acceptable salt thereof as an active ingredient. A pharmaceutical composition for treating nervous diseases contains the urea derivative or a pharmaceutically acceptable salt thereof as an active ingredient.
Abstract:
본 발명은 하기 화학식 1로 표시되는 비스(스티릴)피리미딘 및 비스(스티릴)벤젠 유도체, 이의 약학적으로 허용 가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 베타아밀로이드 집적 관련 질환의 예방 또는 치료용 약학적 조성물에 관한 것으로, 본 발명의 화학식 1의 유도체 화합물은 베타아밀로이드 집적을 저해하고 베타아밀로이드의 독성을 감소시키며, 베타아밀로이드 집적 관련 질환에서 나타나는 학습 및 기억력 저하를 개선시키는 효과를 나타내므로 본 발명에 따른 화학식 1의 유도체 화합물은 베타아밀로이드 집적 관련 질환의 치료에 유용하게 사용될 수 있다. [화학식 1]
(상기 화학식 1에서, 상기 R 1 , R 2 , R 3 및 X는 본 명세서 내에 정의한 바와 같다.) 알츠하이머병 치료제, 베타아밀로이드, 베타아밀로이드 집적 관련 질환